Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advanced or recurrent endometrial cancer
Imfinzi also recommended for patients with mismatch repair deficient disease. Recommendation based on DUO-E Phase III results, which showed both regimens demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemotherapy alone.AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been recommended